News Search Results
Sep 02, 2025, 08:00 ET ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
Europe's leading refractive and cataract surgeons," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "From major industry milestones to new digital workflow solutions, our industry leadership shines bright, setting new
More news about: Carl Zeiss Meditec AG
Sep 02, 2025, 08:00 ET ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
Europe's leading refractive and cataract surgeons," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "From major industry milestones to new digital workflow solutions, our industry leadership shines bright, setting new
More news about: Carl Zeiss Meditec AG
Sep 02, 2025, 07:30 ET EyeCool Therapeutics Appoints Dr. Vance Thompson to Board of Directors
School of Medicine. She is the Associate Editor for the Journal of Refractive Surgery, and on the editorial board of Ophthalmology. Dr. Henderson completed her ophthalmology residency at Harvard Medical School, Massachusetts Eye and Ear Infirmary. She graduated from
More news about: EyeCool Therapeutics, Inc.
Aug 29, 2025, 07:30 ET YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
laboratory, and a monitoring test for recurrent breast cancer, expected to launch as an LDT later this year.Stem Cell- and Exosome-Based Ophthalmology Therapies: In partnership with 3D Global Biotech, the Company is advancing corneal stem cell and exosome technologies for the treatment of ocular
More news about: YD Bio Limited
Aug 28, 2025, 12:52 ET What's Driving Dermatology Practice Sales in 2025 and the 2026 Outlook
the past two decades, private equity and MSO buyers have transformed the ownership landscape across specialties like dental, physical therapy, ophthalmology, and veterinary medicine. Now, dermatology is undergoing a similar shift and creating significant opportunities for those preparing for a dermatology
More news about: TUSK Practice Sales
Aug 28, 2025, 12:03 ET Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Aug 28, 2025, 11:58 ET Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Aug 28, 2025, 11:15 ET Orthopedic Braces & Supports Market worth US$5.5 billion by 2030 with 6.5% CAGR | MarketsandMarkets™
market in 2024. Established in 2002 via the merger of ZEISS Ophthalmology and Asclepion-Meditec AG, it operates as a subsidiary of Carl Zeiss AG. With around 5,730 employees, the company ranks first in microsurgery and second in ophthalmology worldwide. Its high-end surgical microscopes, including the
More news about: MarketsandMarkets
Aug 28, 2025, 09:15 ET Renowned Specialist to Lead New Dry Eye Service at NYU Langone Eye Center
complex eye conditions," said Kathryn A. Colby, MD, PhD, chair of the Department of Ophthalmology, and the Elisabeth J. Cohen, MD, Professor of Ophthalmology. In her new role, Dr. Massaro-Giordano, as director of dry eye services, will deliver an in-demand specialty
More news about: NYU Langone Health
Aug 27, 2025, 06:08 ET Innovent Announces 2025 Interim Results and Business Updates
company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu,
More news about: Innovent Biologics
Aug 26, 2025, 17:31 ET Cataract Surgery Complications Market Insights upto 2034: Key Trends, Growth Drivers, and Forecasts | DelveInsight
feedback from the FDA's Ophthalmology Division, confirming that its U.S. Phase II trial of VVN461LD can be counted as one of two pivotal studies required for NDA submission, reducing the need for just one additional Phase III trial. Phase II data have been published in Ophthalmology Science, and a
More news about: DelveInsight Business Research, LLP
Aug 26, 2025, 10:15 ET Surgical Microscopes Market worth US$2.69 billion by 2030 with 11.4% CAGR | MarketsandMarkets™
market in 2024. Established in 2002 via the merger of ZEISS Ophthalmology and Asclepion-Meditec AG, it operates as a subsidiary of Carl Zeiss AG. With around 5,730 employees, the company ranks first in microsurgery and second in ophthalmology worldwide. Its high-end surgical microscopes, including the
More news about: MarketsandMarkets
Aug 26, 2025, 09:00 ET Eyebot Raises $20 Million Series A Led by General Catalyst to Expand Access to Vision Care
Board, led by Eyebot Chief Medical Officer, Dr. Alexander Martin, that includes leaders from both optometry and ophthalmology. Solving the Real Access Gap In the US alone, more than 3 million people have vision impairment, and an additional 8 million
More news about: Eyebot
Aug 26, 2025, 08:54 ET $504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
specialist on-site. This recruitment initiative leverages Fortrea, a globally recognized contract research organization with specialized ophthalmology expertise, to capture patient data primarily from community clinics and primary care facilities. Such an approach generates real-world evidence
More news about: USA News Group
Aug 26, 2025, 08:00 ET LEADING US MEDICAL CENTER CHOOSES SECTRA'S ENTERPRISE IMAGING CLOUD SERVICE TO STREAMLINE DIAGNOSTIC WORKFLOWS FOR IMPROVED PATIENT CARE
worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, genomics and ophthalmology), and a robust VNA. Over the last consecutive twelve years, Sectra has been awarded Best in KLAS for highest customer satisfaction. For more information,
More news about: Sectra
Aug 26, 2025, 08:00 ET ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA
empower clinicians who are redefining vitreoretinal surgery and advance retinal care," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "We're excited to continue leading in this area and meeting the evolving needs of surgeons from around the world with
More news about: Carl Zeiss Meditec AG
Aug 26, 2025, 08:00 ET ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA
empower clinicians who are redefining vitreoretinal surgery and advance retinal care," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "We're excited to continue leading in this area and meeting the evolving needs of surgeons from around the world with
More news about: Carl Zeiss Meditec AG
Aug 26, 2025, 05:03 ET Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Aug 26, 2025, 04:58 ET Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Aug 25, 2025, 10:02 ET Barti Raises $12M Series A to Accelerate AI-Powered EHR for Eye Care
go-to-market efforts, grow its team across key functions, and accelerate development of new AI capabilities and workflow automation as Barti expands into ophthalmology. The company will also continue expanding its integrated features to drive greater efficiency for practices and solidify its position as the complete
More news about: Five Elms Capital; Barti
Aug 24, 2025, 20:00 ET Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND)
More news about: Innovent Biologics
Aug 22, 2025, 10:01 ET Epigenetics Market is expected to generate a revenue of USD 3.70 Billion by 2031, Globally, at 13.94% CAGR: Verified Market Research®
Size By Therapy Type (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), By Application (Oncology, Genetic Disorders, Rare Diseases, Ophthalmology), By End-user (Hospitals, Cancer Care Centers, Pharmaceutical and Biotechnology Companies), By Geography, And Forecast
More news about: Verified Market Research
Aug 22, 2025, 01:00 ET Medical Equipment Maintenance Market worth US$101.52 billion by 2030 with 10.8% CAGR | MarketsandMarkets™
radiotherapy devices, laboratory equipment, endoscopic devices, medical lasers, electrosurgical equipment, dental equipment, radiotherapy devices, ophthalmology equipment, and durable medical equipment. The diagnostic imaging equipment segment will dominate the market during the forecast period. Continuous
More news about: MarketsandMarkets
Aug 21, 2025, 17:31 ET VEGFR-2 Inhibitors Market Set to Transform Oncology Treatment Landscape by 2034 | DelveInsight
among others, highlights sustained innovation and intensifying competition, positioning the market for continued growth across both oncology and ophthalmology sectors. Rivoceranib is a highly selective VEGFR-2 inhibitor with minimal activity against other tyrosine kinases, offering a focused
More news about: DelveInsight Business Research, LLP
Aug 21, 2025, 08:00 ET ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics
More news about: Carl Zeiss Meditec AG